CNS Drugs

, Volume 10, Issue 1, pp 43–59 | Cite as

Cocaine Abuse and Dependence

Approaches to Management
  • Kalpana I. Nathan
  • William H. Bresnick
  • Steven L. Batki
Disease Management


Cocaine abuse and dependence constitute major health and social problems in the US and elsewhere. They are associated with a wide range of psychiatric and medical morbidity, including an increased risk of transmission of HIV.

The 2 major approaches to the treatment of cocaine abuse and dependence are psychosocial interventions and pharmacotherapy to reduce withdrawal and craving, and to ensure abstinence initiation and relapse prevention. These approaches are often combined to optimise outcome. Numerous medications have been tested in the treatment of cocaine dependence. To date, however, there is no conclusive evidence in support of any generally effective pharmacotherapy for cocaine craving, withdrawal or abstinence initiation. Therefore, the mainstay of treatment is the use of psychosocial interventions.


Cocaine Adis International Limited Fluoxetine Bromocriptine Desipramine 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association, 1994Google Scholar
  2. 2.
    Goldstein A. The wild addictions: cocaine and amphetamines. In: Addiction: from biology to drug policy. New York (NY): W.H. Freeman and Company, 1994: 155–67Google Scholar
  3. 3.
    Benowitz N. Clinical pharmacology and toxicology of cocaine. Pharmacol Toxicol 1993; 72: 3–12PubMedCrossRefGoogle Scholar
  4. 4.
    Jones RT. The pharmacology of cocaine. In: Grabowski J, editor. Cocaine: pharmacology, effects, and treatment of abuse. NIDA Res Monogr 1984; 50: 34–53Google Scholar
  5. 5.
    Gold MS. The neurobiology of addictive disorders: the role of dopamine, endorphin and serotonin. In: Miller NS, editor. The principles and practice of addictions in psychiatry. Philadelphia: W.B. Saunders Company, 1997: 57–69Google Scholar
  6. 6.
    Gawin FH, Kleber HD. Abstinence symptomatology and psychiatric diagnosis in cocaine abusers. Arch Gen Psychiatry 1986; 43: 107–13PubMedCrossRefGoogle Scholar
  7. 7.
    Lago JA, Kosten TR. Stimulant withdrawal. Addiction 1994; 89(11): 1477–81PubMedCrossRefGoogle Scholar
  8. 8.
    Gawin FH. Cocaine addiction: psychology and neurophysiology. Science 1991; 251: 1580–6PubMedCrossRefGoogle Scholar
  9. 9.
    Preliminary estimates from the 1995 National Household Survey on Drug Abuse (NHSDA). 95hhs/ar18txt.htmGoogle Scholar
  10. 10.
    Preliminary estimates from the Drug Abuse Warning Network (DAWN): 1996 DAWN survey. 96dawn/ar17.htmGoogle Scholar
  11. 11.
    Larrat EP, Ziegler S. Entangled epidemics: cocaine use and HIV disease. J Psychoactive Drugs 1993; 25(3): 207–21PubMedCrossRefGoogle Scholar
  12. 12.
    Goldstein PJ, Oullet LJ, Fendrich M. From bags brides to skeezers: a historical perspective on sex-for-drugs behavior. J Psychoactive Drugs 1992; 24(4): 349–61PubMedCrossRefGoogle Scholar
  13. 13.
    Haim DY, Lippmann ML, Goldberg SK, et al. The pulmonary complications of crack cocaine: a comprehensive review. Chest 1995; 107: 233–40PubMedCrossRefGoogle Scholar
  14. 14.
    O’Connor PG, Chang G, Shi J. Medical complications of cocaine use. In: Kosten TR, Kleber HD, editors. Clinician’s guide to cocaine addiction: theory, research and treatment. New York/London: The Guilford Press, 1992: 241–72Google Scholar
  15. 15.
    Fox CH. Cocaine use in pregnancy. J Am Board Fam Pract 1994; 7: 225–8PubMedGoogle Scholar
  16. 16.
    Halikas JA, Crosby RD, Pearson VL, et al. Psychiatric comorbidity in treatment-seeking cocaine abusers. Am J Addict 1994; 3(1): 25–35Google Scholar
  17. 17.
    Ziedonis DM, Rayford BS, Bryant KJ, et al. Psychiatric comorbidity in whites and African-American cocaine addicts seeking substance abuse treatment. Hosp Community Psychiatry 1994; 45(1): 43–9PubMedGoogle Scholar
  18. 18.
    Kleinman PA, Miller AB, Millman RB, et al. Psychopathology among cocaine abusers entering treatment. J Nerv Ment Dis 1990; 178(7): 442–7PubMedCrossRefGoogle Scholar
  19. 19.
    Des Jarlais DC. Harm reduction: a framework for incorporating science in drug policy. Am J Pub Health 1995; 85(1): 10–2CrossRefGoogle Scholar
  20. 20.
    American Psychiatric Association. Practice guidelines for the treatment of patients with substance use disorders: alcohol, cocaine, opioids. Am J Psychiatry 1995; 152(11 Suppl.): 1–59Google Scholar
  21. 21.
    Budde D, Rounsaville B, Bryant K. Inpatient and outpatient cocaine abusers: clinical comparisons at intake and one-year follow-up. J Subst Abuse Treat 1992; 9(4): 337–42PubMedCrossRefGoogle Scholar
  22. 22.
    Alterman AI, O’Brien CP, McLellan AT, et al. Effectiveness and costs of inpatient versus day hospital cocaine rehabilitation. J Nerv Ment Dis 1994; 182(3): 157–63PubMedCrossRefGoogle Scholar
  23. 23.
    United States General Accounting Office. Cocaine treatment: early results from various approaches. Washington, DC: US Government Printing Office, 1996 Jun: 1–34Google Scholar
  24. 24.
    Schuckit MA. Drug and alcohol abuse: a clinical guide to diagnosis and treatment. 4th ed. New York (NY): Plenum, 1995: 328–30Google Scholar
  25. 25.
    Carroll KM, Rounsaville BJ, Keller DS. Relapse prevention strategies for the treatment of cocaine abuse. Am J Drug Alcohol Abuse 1991; 17(3): 249–65PubMedCrossRefGoogle Scholar
  26. 26.
    Carroll KM, Rounsaville BJ, Gawin FH. A comparative trial of psychotherapies for ambulatory cocaine abusers: relapse prevention and interpersonal psychotherapy. Am J Drug Alcohol Abuse 1991; 17(3): 229–47PubMedCrossRefGoogle Scholar
  27. 27.
    Carroll KM, Rounsaville BJ, Gordon LT, et al. Psychotherapy and pharmacotherapy for ambulatory cocaine abusers. Arch Gen Psychiatry 1994; 51: 177–87PubMedCrossRefGoogle Scholar
  28. 28.
    Wallace BC. Treating crack cocaine dependence: the critical role of relapse prevention. J Psychoactive Drugs 1992; 24(2): 213–22PubMedCrossRefGoogle Scholar
  29. 29.
    Higgins ST, Budney AJ. Treatment of cocaine dependence through the principles of behavior analysis and behavioral pharmacology. In: Onken LS, Blaine JD, Boren JJ, editors. Behavioral treatments for drug abuse and dependence. NIDA Res Monogr 1993: 139: 97–121Google Scholar
  30. 30.
    Higgins ST, Budney AJ, Bickel WK, et al. Achieving cocaine abstinence with a behavioral approach. Am J Psychiatry 1993; 150(5): 763–8PubMedGoogle Scholar
  31. 31.
    Higgins ST, Budney AJ, Bickel WK, et al. Incentives improve outcome in outpatient behavioral treatment of cocaine dependence. Arch Gen Psychiatry 1994; 51: 568–76PubMedCrossRefGoogle Scholar
  32. 32.
    Silverman K, Higgins ST, Brooner RK, et al. Sustained cocaine abstinence in methadone maintenance patients through voucher-based reinforcement therapy. Arch Gen Psychiatry 1996; 53: 409–15PubMedCrossRefGoogle Scholar
  33. 33.
    Rawson RA, Obert JL, McCann MJ, et al. Psychological approaches for the treatment of cocaine dependence: a neurobehavioral approach. J Addictive Dis 1991; 11(2): 97–119CrossRefGoogle Scholar
  34. 34.
    Shoptaw S, Rawson RA, McCann MJ, et al. The matrix model of outpatient stimulant abuse treatment: evidence of efficacy. J Addict Dis 1994; 13(4): 129–41PubMedCrossRefGoogle Scholar
  35. 35.
    Hoffman JA, Caudill BD, Koman JJ, et al. Psychosocial treatments for cocaine abuse: 12-month treatment outcomes. J Subst Abuse Treat 1996; 13(1): 3–11PubMedCrossRefGoogle Scholar
  36. 36.
    Frawley PJ, Smith JW. Chemical aversion therapy in the treatment of cocaine dependence as part of a multimodal treatment program: treatment outcome. J Subst Abuse Treat 1990; 7: 21–9PubMedCrossRefGoogle Scholar
  37. 37.
    Smith MO. Acupuncture treatment for crack: clinical survey of 1500 patients treated. Am J Acupuncture 1988; 16: 241–7Google Scholar
  38. 38.
    Margolin A, Avants SK, Chang C, et al. Acupuncture for the treatment of cocaine dependence in methadone-maintained patients. Am J Addict 1993; 2(3): 194–201Google Scholar
  39. 39.
    Avants SK, Margolin A, Chang P, et al. Acupuncture for the treatment of cocaine addiction: investigation of a needle puncture control. J Subst Abuse Treat 1995; 12(3): 195–205PubMedCrossRefGoogle Scholar
  40. 40.
    Johnson DN, Vocci FJ. Medications development at the National Institute on Drug Abuse: cocaine. NIDA Res Monogr 1993; 135: 57–70PubMedGoogle Scholar
  41. 41.
    Landry DW. Immunotherapy for cocaine addiction. Sci Am 1997 Feb; 276(2): 42–5PubMedCrossRefGoogle Scholar
  42. 42.
    Kosten TR, Morgan CM, Falcione J, et al. Pharmacotherapy for cocaine-abusing methadone-maintained patients using amantadine or desipramine. Arch Gen Psychiatry 1992; 49: 894–8PubMedCrossRefGoogle Scholar
  43. 43.
    Handelsman L, Limpitlaw L, Williams D, et al. Amantadine does not reduce cocaine use or craving in cocaine-dependent methadone maintenance patients. Drug Alcohol Depend 1995; 39(3): 173–80PubMedCrossRefGoogle Scholar
  44. 44.
    Kampman K, Volpicelli JR, Alterman A, et al. Amantadine in the early treatment of cocaine dependence: a double-blind, placebo-controlled trial. Drug Alcohol Depend 1996; 41(1): 25–33PubMedCrossRefGoogle Scholar
  45. 45.
    Alterman AI, Droba M, Antelo RE, et al. Amantadine may facilitate detoxification of cocaine addicts. Drug Alcohol Depend 1992; 31(1): 19–29PubMedCrossRefGoogle Scholar
  46. 46.
    Margolin A, Kosten TR, Avants SK, et al. A multicenter trial of bupropion for cocaine dependence in methadone-maintained patients. Drug Alcohol Depend 1995; 40: 125–31PubMedCrossRefGoogle Scholar
  47. 47.
    Giannini AJ, Baumgartel P, DiMarzio LR. Bromocriptine therapy in cocaine withdrawal. J Clin Pharmacol 1987; 27: 267–70PubMedGoogle Scholar
  48. 48.
    Preston KL, Sullivan JT, Strain EC, et al. Effects of cocaine alone and in combination with bromocriptine in human cocaine abusers. J Pharmacol Exp Ther 1992; 292: 279–91Google Scholar
  49. 49.
    Moscovitz H, Brookoff D, Nelson L. A randomized trial of bromocriptine for cocaine users presenting to the emergency department. J Gen Intern Med 1993; 8: 1–4PubMedCrossRefGoogle Scholar
  50. 50.
    Handelsman L, Rosenblum A, Palij M, et al. Bromocriptine for cocaine dependence: a controlled clinical trial. Am J Addict 1997; 6(1): 54–64PubMedGoogle Scholar
  51. 51.
    Oliveto AH, Kosten TR, Schottenfeld R, et al. Cocaine use in buprenorphine vs methadone-maintained patients. Am J Addict 1994; 3(1): 43–8Google Scholar
  52. 52.
    Hatsukami D, Keenan R, Halikas J, et al. Effects of carbamazepine on acute responses to smoked cocaine-base in human cocaine users. Psychopharmacology 1991; 104: 120–4PubMedCrossRefGoogle Scholar
  53. 53.
    Cornish JW, Maany I, Fudala PJ, et al. Carbamazepine treatment for cocaine dependence [abstract]. 147th Annual Meeting of the American Psychiatric Association, 1994 May 21-6; PhiladelphiaGoogle Scholar
  54. 54.
    Gawin FH, Kleber H, Byck R, et al. Desipramine facilitation of initial cocaine abstinence. Arch Gen Psychiatry 1989; 46: 117–21PubMedCrossRefGoogle Scholar
  55. 55.
    Levin FR, Lehman AF. Meta-analysis of desipramine as an adjunct in the treatment of cocaine addiction. J Clin Pharmacol 1991; 11(6): 374–8Google Scholar
  56. 56.
    Arndt IO, Dorozynsky L, Woody GE, et al. Desipramine treatment of cocaine dependence in methadone-maintained patients. Arch Gen Psychiatry 1992; 49(11): 888–93PubMedCrossRefGoogle Scholar
  57. 57.
    Carroll KM, Rounsaville BJ, Gordon LT, et al. Psychotherapy and pharmacotherapy for ambulatory cocaine abusers. Arch Gen Psychiatry 1994; 51: 177–87PubMedCrossRefGoogle Scholar
  58. 58.
    Hall SM, Tunis S, Triffleman E, et al. Continuity of care and desipramine in primary cocaine abusers. J Nerv Ment Dis 1994; 182(10): 570–5PubMedGoogle Scholar
  59. 59.
    Batki SL, Washburn AM, Delucchi K, et al. Acontrolled trial of fluoxetine in crack cocaine dependence. Drug Alcohol Depend 1996; 41: 137–42PubMedCrossRefGoogle Scholar
  60. 60.
    Grabowski J, Rhoades H, Elk R, et al. Fluoxetine is ineffective for treatment of cocaine dependence or concurrent opiate and cocaine dependence: two placebo-controlled, double-blind trials. J Clin Psychopharmacol 1995; 15(3): 163–74PubMedCrossRefGoogle Scholar
  61. 61.
    Covi L, Hess JM, Kreiter NA, et al. Effects of combined fluoxetine and counseling in the outpatient treatment of cocaine abusers. Am J Drug Alcohol Abuse 1995; 21(3): 327–44PubMedCrossRefGoogle Scholar
  62. 62.
    Galloway GP, Newmeyer J, Knapp T, et al. Imipramine for the treatment of cocaine and methamphetamine dependence. J Addict Dis 1994; 13(4): 201–16PubMedCrossRefGoogle Scholar
  63. 63.
    Nunes EV, McGrath PJ, Quitkin FM, et al. Imipramine treatment of cocaine abuse: possible boundaries of efficacy. Drug Alcohol Depend 1995; 39(3): 185–95PubMedCrossRefGoogle Scholar
  64. 64.
    Wolfsohn R, Angrist B. A pilot trial of levodopa/carbidopa in early cocaine abstinence. J Clin Psychopharmacol 1990; 10(6): 440–2PubMedGoogle Scholar
  65. 65.
    Chadwick MJ, Gregory DL, Wendung G. A double-blind amino acids, L-tryptophan and L-tyrosine, and placebo study with cocaine-dependent subjects in an inpatient chemical dependency treatment center. Am J Drug Abuse 1990; 16(3–4): 275–86CrossRefGoogle Scholar
  66. 66.
    Kosten TR, Steinberg M, Diakogiannis IA. Crossover trial of mazindol for cocaine dependence. Am J Addict 1993; 2(2): 161–4Google Scholar
  67. 67.
    Preston KL, Sullivan JT, Berger P. Effects of cocaine alone and in combination with mazindol in human cocaine users. J Pharmacol Exp Ther 1993; 267: 296–307PubMedGoogle Scholar
  68. 68.
    Margolin A, Avants SK, Kosten TR. Mazindol for relapse prevention to cocaine abuse in methadone-maintained patients. Am J Drug Alcohol Abuse 1995; 21(4): 469–81PubMedCrossRefGoogle Scholar
  69. 69.
    Stine SM, Krystal JH, Kosten TR, et al. Mazindol treatment for cocaine dependence. Drug Alcohol Depend 1995; 39(3):245–52PubMedCrossRefGoogle Scholar
  70. 70.
    Wiseman EJ, McMillan DE. Transdermal nicotine and drug craving. Am J Addict 1995; 4(3): 261–6CrossRefGoogle Scholar
  71. 71.
    Muntaner C, Kumor KM, Nagoshi C, et al. Effects of nifedipine pretreatment on subjective and cardiovascular responses to intravenous cocaine in humans. Psychopharmacology 1991; 105(1): 37–51PubMedCrossRefGoogle Scholar
  72. 72.
    Crosby RD, Pearson VL, Eller C, et al. Phenytoin in the treatment of cocaine abuse: a double-blind study. Clin Pharmacol Ther 1996; 59(4): 458–68PubMedCrossRefGoogle Scholar
  73. 73.
    American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 3rd ed. rev. Washington, DC: American Psychiatric Association, 1987Google Scholar
  74. 74.
    Kosten TR, Schumann B, Wright D, et al. A preliminary study of desipramine in the treatment of cocaine abuse in methadone maintenance patients. J Clin Psychiatry 1987; 48(11): 442–4PubMedGoogle Scholar
  75. 75.
    Fischman MW, Foltin RW, Nestadt G, et al. Effects of desipramine maintenance on cocaine self-administration by humans. J Pharmacol Exp Ther 1990; 253(2): 760–70PubMedGoogle Scholar
  76. 76.
    Foltin RW, Fischman MW, Levin FR. Cardiovascular effects of cocaine in humans: laboratory studies. Drug Alcohol Depend 1995; 37(3): 193–210PubMedCrossRefGoogle Scholar
  77. 77.
    Nunes EV, Quitkin FM, Brady R, et al. Imipramine treatment of methadone maintenance patients with affective disorder and illicit drug use. Am J Psychiatry 1991; 148(5): 667–9PubMedGoogle Scholar
  78. 78.
    Batki SL, Manfredi LB, Jacob P, et al. Fluoxetine for cocaine dependence in methadone maintenance: quantitative plasma and urine cocaine/benzoylecgonine concentrations. J Clin Psychopharmacol 1993; 13(4): 243–50PubMedCrossRefGoogle Scholar
  79. 79.
    Batki SL, Washburn A, Manfredi LB, et al. Fluoxetine in primary and secondary cocaine dependence: outcome measured by quantitative benzoylecgonine concentration [abstract]. NIDA Res Monog; 141: 140, National Institute on Drug Abuse, NIH Public. No. 94-3749. Rockville (MD): US Department of Health and Human Services, 1994Google Scholar
  80. 80.
    Walsh SL, Preston KL, Sullivan JT, et al. Fluoxetine alters the effects of intravenous cocaine in humans. J Clin Psychopharmacol 1994; 14(6): 396–407PubMedCrossRefGoogle Scholar
  81. 81.
    Hollister LE, Krajewski K, Rustin T, et al. Drugs for cocaine dependence: not easy [letter]. Arch Gen Psychiatry 1992; 49: 905PubMedCrossRefGoogle Scholar
  82. 82.
    Montoya ID, Preston KL, Cone EJ, et al. Safety and efficacy of bupropion combined with bromocriptine for treatment of cocaine dependence. Am J Addict 1996; 5(1): 69–76Google Scholar
  83. 83.
    Halikas JA, Kuhn KL, Maddux TL. Reduction of cocaine use among methadone maintenance patients using concurrent carbamazepine. Ann Clin Psychiatry 1990; 2: 3–6CrossRefGoogle Scholar
  84. 84.
    Berger P, Gawin F, Kosten TR. Treatment of cocaine abuse with mazindol [letter]. Lancet 1989 Feb; I: 283CrossRefGoogle Scholar
  85. 85.
    Khantzian EJ, Gawin FH, Kleber HD, et al. Methylphenidate treatment of cocaine dependence — a preliminary report. J Subst Abuse Treat 1984; 1: 107–12PubMedCrossRefGoogle Scholar
  86. 86.
    Kosten TR, Kleber HD, Morgan CH. Treatment of cocaine abuse with buprenorphine. Biol Psychiatry 1989; 26: 637–9PubMedCrossRefGoogle Scholar
  87. 87.
    Kosten TR, Kleber HD, Morgan C. Role of opioid antagonists in treating intravenous cocaine abuse. Life Sci 1989; 44: 887–92PubMedCrossRefGoogle Scholar
  88. 88.
    Wolfsohn R, Sanfilipo M, Angrist B. A placebo-controlled trial of L-dopa/carbidopa in early cocaine abstinence. Neuropsychopharmacology 1993; 9: 49–53PubMedGoogle Scholar
  89. 89.
    Higgins ST, Budney AJ, Bickel WK, et al. Disulfiram therapy in patients abusing cocaine and alcohol. Am J Psychiatry 1993; 150(4): 675–6PubMedGoogle Scholar
  90. 90.
    Carroll KM, Ziedonis D, O’Malley SS, et al. Pharmacological interventions for abusers of alcohol and cocaine: disulfiram versus naltrexone. Am J Addict 1993; 2: 77–9CrossRefGoogle Scholar
  91. 91.
    Gawin FH, Khalsa-Denison EM, Jatlow P. Flupenthixol-induced aversion to crack cocaine. N Engl J Med 1996; 334(20): 1340–1PubMedCrossRefGoogle Scholar
  92. 92.
    Gawin FH, Allen D, Humblestone B. Outpatient treatment of ‘crack’ cocaine smoking with flupenthixol decanoate. Arch Gen Psychiatry 1989; 46: 322–5PubMedCrossRefGoogle Scholar
  93. 93.
    Khouzam HR, Mayo-Smith MF, Bernard DR, et al. Treatment of crack-cocaine-induced compulsive behavior with trazo-done. J Subst Abuse Treat 1995; 12(2): 85–8PubMedCrossRefGoogle Scholar
  94. 94.
    Kosten TA, Kosten TR, Gawin FH. An open trial of sertraline for cocaine abuse. Am J Addict 1992; 1(4): 349–53Google Scholar
  95. 95.
    Goldwyn DH. Cocaine abuse treated with phenelzine. Int J Addict 1988; 23(9): 897–905Google Scholar
  96. 96.
    Margolin A, Avants SK, Falcioni J, et al. Preliminary investigation of selegiline for the treatment of cocaine dependence. Am J Addict 1996; 15(3): 275–6CrossRefGoogle Scholar
  97. 97.
    Margolin A, Avants SK, Kosten TR. Pemoline for the treatment of cocaine dependence in methadone-maintained patients. J Psychoactive Drugs 1996; 28(3): 301–4PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 1998

Authors and Affiliations

  • Kalpana I. Nathan
    • 1
    • 2
  • William H. Bresnick
    • 1
    • 2
  • Steven L. Batki
    • 1
    • 2
  1. 1.Department of PsychiatryUniversity of California at San Francisco, School of MedicineSan FranciscoUSA
  2. 2.Division of Substance Abuse and Addiction MedicineSan Francisco General HospitalSan FranciscoUSA

Personalised recommendations